Disorders in cell circuitry associated with multistage carcinogenesis: exploitable targets for cancer prevention and therapy.

The development of a malignant tumor involves the progressive acquisition of mutations and epigenetic abnormalities in multiple genes that have highly diverse functions. Some of these genes code for pathways of signal transduction that mediate the action of growth factors. The enzyme protein kinase C plays an important role in these events and in the process of tumor promotion. Therefore, we examined the effects of three inhibitors of protein kinase C, CGP 41251, RO 31-8220, and calphostin C, on human glioblastoma cells. These compounds inhibited growth and induced apoptosis; these activities were associated with a decrease in the level of CDC2 and cyclin B1/CDC2-associated kinase activity. This may explain why the treated cells accumulated in G2-M. In a separate series of studies, we examined abnormalities in cell cycle control genes in human cancer. We have found that cyclin D1 is frequently overexpressed in a variety of human cancers. Mechanistic studies indicate that cyclin D1 can play a critical role in carcinogenesis because: overexpression enhances cell transformation and tumorigenesis; introduction of an antisense cyclin D1 cDNA into either human esophageal or colon cancer cells reverts their malignant phenotype; and overexpression of cyclin D1 can enhance the amplification of other genes. The latter finding suggests that cyclin D1 can enhance genomic instability and, thereby, the process of tumor progression. Therefore, inhibitors of the function of cyclin D1 may be useful in both cancer chemoprevention and therapy. We obtained evidence for the existence of homeostatic feedback loops between cyclins D1 or E and the cell cycle inhibitory protein p27Kip1. On the basis of these and other findings, we hypothesize that, because of their disordered circuitry, cancer cells suffer from "gene addiction" and "gene hypersensitivity," disorders that might be exploited in both cancer prevention and therapy.

[1]  C. Harris,et al.  Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[2]  Y. Doki,et al.  Increased expression of the P27KIP1 protein in human esophageal cancer cell lines that over-express cyclin D1. , 1997, Carcinogenesis.

[3]  Y. Doki,et al.  Increased expression of the P 27 KIP 1 protein in human esophageal cancer cell lines that over-express cyclin D 1 , 1997 .

[4]  H. Lovec,et al.  Cyclin D1/bcl‐1 cooperates with myc genes in the generation of B‐cell lymphoma in transgenic mice. , 1994, The EMBO journal.

[5]  Pengcheng Zhou,et al.  Overexpression of cyclin D1 in rat fibroblasts causes abnormalities in growth control, cell cycle progression and gene expression. , 1993, Oncogene.

[6]  I. Schieren,et al.  Effects of cyclin E overexpression on cell growth and response to transforming growth factor beta depend on cell context and p27Kip1 expression. , 1997, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[7]  I. Schieren,et al.  Overexpression of cyclin E in the HC11 mouse mammary epithelial cell line is associated with growth inhibition and increased expression of p27(Kip1). , 1996, Cancer research.

[8]  A. Marchetti,et al.  p21 RNA and protein expression in non-small cell lung carcinomas: evidence of p53-independent expression and association with tumoral differentiation. , 1996, Oncogene.

[9]  H. Hibshoosh,et al.  Increased expression of cyclin D1 is an early event in multistage colorectal carcinogenesis. , 1996, Gastroenterology.

[10]  W. Kolch,et al.  PKC epsilon functions as an oncogene by enhancing activation of the Raf kinase. , 1996, Oncogene.

[11]  J. Bartek,et al.  The PRAD‐1/cyclin D1 oncogene product accumulates aberrantly in a subset of colorectal carcinomas , 1994, International journal of cancer.

[12]  G. Cattoretti,et al.  Localization and expression of p27KIP1 in multistage colorectal carcinogenesis. , 1998, Cancer research.

[13]  G. Casey,et al.  Evidence that wild‐type TP53, and not genes on either chromosome 1 or 11, controls the tumorigenic phenotype of the human fibrosarcoma HT1080 , 1994, Genes, chromosomes & cancer.

[14]  Thea D. Tlsty,et al.  Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53 , 1992, Cell.

[15]  I. Schieren,et al.  Antisense to cyclin D1 inhibits growth and reverses the transformed phenotype of human esophageal cancer cells. , 1995, Oncogene.

[16]  M. Kitajima,et al.  Cyclin D1 amplification as a new predictive classification for squamous cell carcinoma of the esophagus, adding gene information. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  A. Harris,et al.  p21WAF1 immunohistochemical expression in breast carcinoma: correlations with clinicopathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein alterations and relapse-free survival. , 1996, British Journal of Cancer.

[18]  I. Weinstein,et al.  Overexpression of cyclin D1 enhances gene amplification. , 1996, Cancer research.

[19]  J. Bartek,et al.  Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. , 1994, Cancer research.

[20]  W. Benedict,et al.  Expression of the retinoblastoma (RB) tumor suppressor gene inhibits tumor cell invasion in vitro. , 1996, Oncogene.

[21]  Emma Lees,et al.  Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice , 1994, Nature.

[22]  Y. Doki,et al.  Antisense to Cyclin Dl Inhibits the Growth and Tumorigenicity of Human Colon Cancer Cells1 , 1997 .

[23]  I. Weinstein.  Relevance of cyclin D1 and other molecular markers to cancer chemoprevention , 1996, Journal of cellular biochemistry. Supplement.

[24]  James M. Roberts,et al.  Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients , 1997, Nature Medicine.

[25]  J. Bartek,et al.  Cyclin D1 expression is regulated by the retinoblastoma protein. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Stephen N. Jones,et al.  Regulation of p53 stability by Mdm2 , 1997, Nature.

[27]  T. Hunter,et al.  Cyclins and cancer II: Cyclin D and CDK inhibitors come of age , 1994, Cell.

[28]  S. Elledge,et al.  Cyclin D1 provides a link between development and oncogenesis in the retina and breast , 1995, Cell.

[29]  G. Wahl,et al.  Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles , 1992, Cell.

[30]  S. Gansauge,et al.  Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis. , 1997, Cancer research.

[31]  R. DuBois,et al.  Concurrent overexpression of cyclin D1 and cyclin-dependent kinase 4 (Cdk4) in intestinal adenomas from multiple intestinal neoplasia (Min) mice and human familial adenomatous polyposis patients. , 1997, Cancer research.

[32]  J. Palazzo,et al.  Immunohistochemical localization of p21(WAF1/CIP1) in normal, hyperplastic, and neoplastic uterine tissues. , 1997, Human pathology.

[33]  Herman Yeger,et al.  Decreased levels of the cell-cycle inhibitor p27Kip1 protein: Prognostic implications in primary breast cancer , 1997, Nature Medicine.

[34]  M. Loda,et al.  Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas , 1997, Nature Medicine.

[35]  D. Fabbro,et al.  Inhibition of the growth of glioblastomas by CGP 41251, an inhibitor of protein kinase C, and by a phorbol ester tumor promoter. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  M. Oren,et al.  Mdm2 promotes the rapid degradation of p53 , 1997, Nature.

[37]  J. Shay,et al.  Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. , 1994, Cancer research.

[38]  F. C. Lucibello,et al.  Oncogenic activity of cyclin D1 revealed through cooperation with Ha-ras: link between cell cycle control and malignant transformation. , 1994, Oncogene.

[39]  A. Iavarone,et al.  Regulated ectopic expression of cyclin D1 induces transcriptional activation of the cdk inhibitor p21 gene without altering cell cycle progression , 1997, Oncogene.

[40]  A. Neugut,et al.  Increased expression of the cyclin D1 gene in Barrett's esophagus. , 1996, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[41]  R. Weinberg,et al.  Function of a human cyclin gene as an oncogene. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[42]  T. Hattori,et al.  Overexpression and localization of cyclin D1 mRNA and antigen in esophageal cancer. , 1995, The American journal of pathology.